TriangleNCT01307579 · OUTCOME
Percentage of Participants That Need Empiric Antifungal Therapy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 months since enrollment
What was measured
The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course.
Analysis population: Evaluable patients (ineligible and inevaluable due to having IFI before IFI monitoring period were excluded)
Groups in this outcome
Arm I (Caspofungin Acetate)
Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins. Caspofungin Acetate: Given IV Laboratory Biomarker Analysis: Correlative studies
Arm II (Fluconazole)
Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course. Fluconazole: Given IV or PO Laboratory Biomarker Analysis: Correlative studies
| Group | Source count |
|---|---|
| Arm I (Caspofungin Acetate) | 253 |
| Arm II (Fluconazole) | 255 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (Caspofungin Acetate) | 71.9 | Not reported | 65.1 | 78.4 | Not reported |
| Arm II (Fluconazole) | 69.5 | Not reported | 63.1 | 75.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 65.1
- upper Limit
- 78.4
- value
- 71.9
- group Id
- OG001
- lower Limit
- 63.1
- upper Limit
- 75.7
- value
- 69.5
- denoms
- counts
- group Id
- OG000
- value
- 253
- group Id
- OG001
- value
- 255
- units
- Participants
- description
- The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins. Caspofungin Acetate: Given IV Laboratory Biomarker Analysis: Correlative studies
- id
- OG000
- title
- Arm I (Caspofungin Acetate)
- description
- Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course. Fluconazole: Given IV or PO Laboratory Biomarker Analysis: Correlative studies
- id
- OG001
- title
- Arm II (Fluconazole)
- param Type
- NUMBER
- population Description
- Evaluable patients (ineligible and inevaluable due to having IFI before IFI monitoring period were excluded)
- reporting Status
- POSTED
- time Frame
- Up to 5 months since enrollment
- title
- Percentage of Participants That Need Empiric Antifungal Therapy
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice